作者
Alberto M. Marra,Roberta D’Assante,M De Luca,Michele Arcopinto,Stefania Paolillo,Valéria Valente,Giulia Crisci,Dario Bruzzese,Stefania Paolillo,Pasquale Perrone Filardi,Giovanna Esposito,Eduardo Bossone,Andrea Salzano,Antonio Cittadini
摘要
Abstract Background Preliminary results of GH deficiency (GHD) correction in Heart Failure (HF) showed an improvement in quality of life, cardiac architecture and function, and cardiovascular performance. Aim of the present double-blind, randomized, placebo-controlled trial was to evaluate the cardiovascular effects of 1 year of GH replacement therapy in a cohort of patients with heart failure and reduced ejection fraction (HFrEF). Methods Consecutive patients with HFrEF in NYHA class I/II/III and concomitant GHD were recruited. GHD patients were randomized to receive GH, (0.012 mg/kg every second day ~2.5 IU), or placebo, on top of background therapy. The primary endpoint was peak oxygen consumption (peak VO2). Secondary endpoints included hospitalizations, end-systolic LV volumes, NT-proBNP levels and Health-related Quality of Life score. Results The study groups consisted of 64 patients, 30 randomized in the active treatment group, and 34 in the control group. After 1 year, a statistically significant improvement of peak VO2 was reached in the active group (from 12.8±3.4 to 15.5±3.15mL/Kg/min, p<0.01; Δ peak VO2 between groups: +3.1 vs -1.8 p<0.01, see figure 1). GH improved LV and RV function (i.e. LV ejection fraction, TAPSE and TAPSE/PASP ratio, p<0.01), leading to an amelioration of clinical status (NYHA class, p<0.05) and health-related quality of life (MLWHFQ, p<0.05). A significant decrease of NT-proBNP was also found (p<0.05). Conclusions This randomized, double-blind, placebo-controlled trial demonstrates that GH replacement therapy in HFrEF patients with GHD improves exercise performance, and LV and RV architecture and function, leading to an amelioration of clinical status and health-related quality of life.